Precision biosciences stock.

After the upgrade, the consensus from Precision BioSciences' five analysts is for revenues of US$37m in 2023, which would reflect a chunky 20% decline in sales compared to the last year of ...Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. [4]13 thg 4, 2021 ... Do you want to earn up to a 4888583% annual return on your money by two trades per day on Precision Biosciences Inc DTIL Stock? Reading this ...

Precision BioSciences shares are trading lower after HC Wainwright maintained a Buy rating on the stock but lowered its price target from $5 to $3. Benzinga Newsdesk - Aug 17, 2023, 11:06AM

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable …

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform …ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues.DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in …Precision BioSciences, Inc. (DTIL) Stock Price | Stock Quote Nasdaq - MarketScreener PRECISION BIOSCIENCES, INC. Precision BioSciences, Inc. Stock …

About us. Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its …

In the last 3 months, 4 analysts have offered 12-month price targets for Precision BioSciences. The company has an average price target of $3.25 with a high of $5.00 and a low of $2.00.

Based on short-term price targets offered by five analysts, the average price target for Precision BioSciences comes to $3.00. The forecasts range from a low of $1.00 to a high of $5.00. The ...Discover historical prices for DTIL stock on Yahoo Finance. View daily, weekly or monthly format back to when Precision BioSciences, Inc. stock was issued.The stock currently has a share float of 51.43%. Precision Biosciences Inc stock is held by 114 institutions, with Great Point Partners LLC being the largest institutional investor. By Jun 29, 2023, it held 6.49% of the shares, which is about 7.47 million shares worth $3.93 million.7 thg 11, 2023 ... DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...7 ngày trước ... DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...

The Investor Relations website contains information about Precision BioSciences's business for stockholders, potential investors, and financial analysts. Shares of Precision BioSciences (DTIL 0.23%) ... As of 1:40 p.m. EST, the stock had settled to a 16.9% gain. The gene-editing stock is up 70% since the beginning of November.According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Precision BioSciences will be entitled to receive an upfront payment of $75 million from NVS. The company is also eligible to receive up to an additional $1.4 billion as future milestone payments ...Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update. May 9, 2023 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding were approximately 111.3 million for the quarter ended March 31, 2023, as compared to approximately 61.0 million for the quarter ended March 31, 2022.

In a report released on November 4, Justin Zelin from BTIG reiterated a Buy rating on Precision BioSciences (DTIL - Research Report), with a price target of $8.00.The companys shares closed last ...

Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ...HC Wainwright Adjusts Price Target on Precision BioSciences to $3 From $5, Keeps Buy Rating. Aug. 17. MT. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT.In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ...Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ...Nov 24, 2023 · Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ... 7 ngày trước ... DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.In June 2022, Precision announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, ... Precision Biosciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts)

However, on July 27, BMO Capital maintained a Hold rating on Precision BioSciences (NASDAQ: DTIL). See the top stocks recommended by analysts >> DTIL market cap is currently $63.96M and has a P/E ...

4 ngày trước ... Precision BioSciences Inc (DTIL:NASDAQ CM) の株価、株式情報、チャート、関連ニュースなど、企業概要や株価の分析をご覧いただけます。

Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform. ARCUS is a highly specific ...Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update. May 9, 2023 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding were approximately 111.3 million for the quarter ended March 31, 2023, as compared to approximately 61.0 million for the quarter ended March 31, 2022.DTIL stock, representing Precision BioSciences Inc, had an interesting performance on September 19, 2023. According to data from CNN Money, the 5 analysts offering 12-month price forecasts for DTIL have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $1.40. This indicates a potential increase of …Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26 Price target decreased by 15% to US$2.60Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Nov 30, 2023 · The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […] Founders Derek Jantz, Jeff Smith, Matthew Kane. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL. Company Type For Profit. Contact Email [email protected]. Phone Number +1 919 314-5512. Precision …Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS ®- based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update. In addition, following the platform-wide …Founders Derek Jantz, Jeff Smith, Matthew Kane. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL. Company Type For Profit. Contact Email [email protected]. Phone Number +1 919 314-5512. Precision …Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable …

28 thg 3, 2019 ... Precision Biosciences, the gene-editing startup, started trading on the Nasdaq stock exchange today after raising a $126.4 million IPO ...DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...Precision BioSciences (NASDAQ:DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a ...Precision BioSciences has a consensus target price of $3.00, suggesting a potential upside of 710.81%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Checkpoint Therapeutics is more favorable than Precision BioSciences.Instagram:https://instagram. nat stock dividendbest altcoin exchangesbest trading options booktdameritrade vs interactive brokers With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Precision BioScience (NASDAQ: DTIL) stock is rallying for a second straight day after the company announced a new partnership with Novartis (NYSE: NVS) after market close yesterday. Novartis is a ... short selling forexipo calender Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. See its stock price, performance, financials, outlook, and news on Google Finance. dental plans in sc Precision BioSciences, Inc. Common Stock (DTIL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Stock Information · Financial Information · Investor Resources ... Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer.DTIL's stock price has decreased by -71.36% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 3 stock analysts, the average 12-month stock price forecast for DTIL stock stock is $3.00, which predicts an increase of 607.88%.